| Vaccine adjuvants as potential cancer immunotherapeutics B Temizoz, E Kuroda, KJ Ishii International immunology 28 (7), 329-338, 2016 | 241 | 2016 |
| TLR9 and STING agonists synergistically induce innate and adaptive type‐II IFN B Temizoz, E Kuroda, K Ohata, N Jounai, K Ozasa, K Kobiyama, T Aoshi, ... European journal of immunology 45 (4), 1159-1169, 2015 | 134 | 2015 |
| Inhaled fine particles induce alveolar macrophage death and interleukin-1α release to promote inducible bronchus-associated lymphoid tissue formation E Kuroda, K Ozasa, B Temizoz, K Ohata, CX Koo, T Kanuma, T Kusakabe, ... Immunity 45 (6), 1299-1310, 2016 | 124 | 2016 |
| Combination and inducible adjuvants targeting nucleic acid sensors B Temizoz, E Kuroda, KJ Ishii Current Opinion in Pharmacology 41, 104-113, 2018 | 44 | 2018 |
| Cyclic GMP-AMP triggers asthma in an IL-33-dependent manner that is blocked by amlexanox, a TBK1 inhibitor K Ozasa, B Temizoz, T Kusakabe, S Kobari, M Momota, C Coban, S Ito, ... Frontiers in Immunology 10, 2212, 2019 | 34 | 2019 |
| B cell‐intrinsic MyD88 signaling controls IFN‐γ‐mediated early IgG2c class switching in mice in response to a particulate adjuvant MSJ Lee, Y Natsume‐Kitatani, B Temizoz, Y Fujita, A Konishi, K Matsuda, ... European Journal of Immunology 49 (9), 1433-1440, 2019 | 21 | 2019 |
| Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells Y Kitahata, T Kanuma, M Hayashi, N Kobayashi, K Ozasa, T Kusakabe, ... Oncotarget 7 (31), 48860, 2016 | 20 | 2016 |
| Species‐dependent role of type I IFNs and IL‐12 in the CTL response induced by humanized CpG complexed with β‐glucan K Kobiyama, B Temizoz, T Kanuma, K Ozasa, M Momota, T Yamamoto, ... European journal of immunology 46 (5), 1142-1151, 2016 | 18 | 2016 |
| CpG ODN (K3)—toll-like receptor 9 agonist—induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study T Otsuka, S Nishida, T Shibahara, B Temizoz, M Hamaguchi, T Shiroyama, ... BMC cancer 22 (1), 744, 2022 | 14 | 2022 |
| B cell–intrinsic TBK1 is essential for germinal center formation during infection and vaccination in mice MSJ Lee, T Inoue, W Ise, J Matsuo-Dapaah, JB Wing, B Temizoz, ... Journal of Experimental Medicine 219 (2), e20211336, 2021 | 13 | 2021 |
| Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation B Temizoz, K Hioki, S Kobari, N Jounai, T Kusakabe, MSJ Lee, C Coban, ... International Immunology 34 (7), 353-364, 2022 | 12 | 2022 |
| TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same K Ishii, E Kuroda, B Temizoz US Patent 11,058,758, 2021 | 11 | 2021 |
| Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain K Kobiyama, M Imai, N Jounai, M Nakayama, K Hioki, ... bioRxiv, 2021.03. 04.433852, 2021 | 9 | 2021 |
| Type I and II interferons toward ideal vaccine and immunotherapy B Temizoz, KJ Ishii Expert Review of Vaccines 20 (5), 527-544, 2021 | 7 | 2021 |
| Machine learning-assisted screening of herbal medicine extracts as vaccine adjuvants K Hioki, T Hayashi, Y Natsume-Kitatani, K Kobiyama, B Temizoz, ... Frontiers in Immunology 13, 847616, 2022 | 3 | 2022 |
| Novel adjuvants B Temizoz, E Kuroda, K Kobiyama, T Aoshi, KJ Ishii Immunotherapy of Cancer: An Innovative Treatment Comes of Age, 247-260, 2016 | 2 | 2016 |
| Particulate-Driven Type-2 immunity and allergic responses E Kuroda, B Temizoz, C Coban, K Ozasa, KJ Ishii Allergy and Immunotoxicology in Occupational Health, 63-82, 2017 | 1 | 2017 |
| Novel thi-inducing adjuvant comprising combination of different nucleic acid adjuvants and use of same K Ishii, E Kuroda, B Temizoz US Patent App. 18/456,044, 2024 | | 2024 |
| 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation B Temizoz, T Shibahara, K Hioki, T Hayashi, K Kobiyama, MSJ Lee, ... Frontiers in Immunology 15, 1353336, 2024 | | 2024 |
| TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model MD Castro Eiro, K Hioki, L Li, MEP Wilmsen, CH Kiernan, ... The Journal of Immunology 212 (3), 455-465, 2024 | | 2024 |
